In a panel of GBM patient tissues, TfR1 and DRD5 expression showed a negative and positive correlation with the expression of the PN marker, SOX2, respectively (Fig. 5f), indicating that the differential expression of these two receptors may contribute to the progression of heterogeneous GBM. This evidence concerns the gene DRD5 and glioblastoma.